NCT00333515View on ClinicalTrials.gov

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 1, 2007

Primary Completion Date

April 1, 2008

Study Completion Date

August 1, 2008

Conditions
Healthy VolunteersChemical TerrorismChemical Warfare
Interventions
DRUG

Human Butyrylcholinesterase (HuBChE) derived from human plasma

Administration via IV infusion at a rate of 50 mg/min (2 mL/min)

DRUG

Placebo: Normal saline

Administration via IV infusion at a rate of 50 mg/min (2 mL/min)

Trial Locations (1)

66219

Quintiles Phase 1 Services, Lenexa

All Listed Sponsors
collaborator

DynPort Vaccine Company LLC, A GDIT Company

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT00333515 - Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously | Biotech Hunter | Biotech Hunter